louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00908999: Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
Official title: FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anosognosia
Alzheimer's Disease
Mild Cognitive Impairment
Keywords: anosognosia fMRI amnestic MCI Alzheimer
anosognosia in AD and MCI
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2009-05-27
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: MCI and AD patients are referred from memory clinics at the UW hospital, William S. Middleton Memorial Veterans Hospital (Madison, WI) and the statewide clinics offered through the Wisconsin Alzheimer's Institute (WAI).

Brief summary: This is a three year fMRI study conducted at the University of Wisconsin (UW) Hospital and the William. S. Middleton VA Hospital. This study is guided by the hypothesis that reduced fMRI activity and connectivity cortical midline structures (i.e., medial frontal and ventral posterior cingulate cortex) are physiologic abnormalities that relate strongly to the compromised insight into cognitive deficits, or anosognosia, shown by a subset of individuals with amnestic MCI (aMCI) and AD. Further, the investigators hypothesize that these regional changes in fMRI activity are predictive of faster progression from aMCI to AD.


Eligibility criteria: Inclusion Criteria:

* Amnestic MCI:

  1. Observation of memory decline by informant.
  2. Mini Mental Status Exam (MMSE) score between 24 and 30.
  3. Objective memory impairment on neuropsychological tests.
  4. Intact functional abilities, and 4) no diagnosis of dementia.
* AD:

  1. A diagnosis of probable AD according with the NINDS-ADRDA and DSM-IV diagnostic criteria.
  2. MMSE score between 16 and 27. All AD patients will have capacity to provide informed consent as judged by the referring physician.

Exclusion Criteria:

* MRI incompatibility; history of neurologic disease (including prior loss of consciousness of more than 10 minutes); prior neurosurgery; or chronic medical diseases (such as poorly controlled diabetes, renal disease, or poorly controlled hypertension).
* Excluded medications include neuroleptics, short or long acting nitrates, and Warfarin.
* Other exclusions include: less than 10 yrs of education; Hachinski scale of 4 or more; first language other than English; poor visual or auditory acuity; pregnancy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: William S Middleton VA Hospital GRECC
state: Wisconsin
Study officials:
References:
Clinical trial NCT06458699: Management Of Stoma In Patients Younger Than 3 Months Old
Official title: Management of Ostomy in Neonates: A Retrospective Single-Center Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Stoma Colostomy
Stoma Ileostomy
Neonatal Disease
Keywords: Ostomy
Neonate
Outcomes
Costs
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2024-06-14
Enrollment: 82
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neonates whose disease require a stoma during the first 3 months of life, from January 2009 to December 2023

Brief summary: Indications for jejunostomy, ileostomy or colostomy vary in the neonatal population. The most common etiologies are congenital anomalies, such as anorectal malformations, intestinal atresia or Hirschsprung's disease, but also acquired conditions, such as enterocolitis or intestinal perforation. The aim of these stomas is to divert stool in the event of intestinal obstruction or risk of fecal contamination.

Depending on the indication and the type of stoma used, the post-operative follow-up, such as resumption of intestinal transit and feeding, secondary closure of the stoma or not, and the duration and cost of hospitalization differ.

The aim of this study is to compare these differences in order to extract an optimal management strategy, in the light of what is reported in the international scientific literature.

Detailed description: The investigators gathered the data of patients born between January 2009 and December 2023, who had an ostomy made during the first three months of their life.

The investigators then analyzed the patients outcomes ( postoperative complications, length of stay, cost of hospitalization) depending on the etiology of their primary disease.

Eligibility criteria: Inclusion Criteria:

* Patients who had a stoma during the first 3 months of life, from January 2009 to December 2023

Exclusion Criteria:

* Patients who had a stoma after the first 3 months of life, from January 2009 to December 2023
* Patients without a stoma

Primary outcomes:
measure: Postoperative medical complications
timeFrame: through study completion, an average of 1 year
measure: Postoperative surgical complications
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Length of stay
timeFrame: through study completion, an average of 1 year
measure: Hospitalization costs
timeFrame: through study completion, an average of 1 year
Other outcomes:
measure: Redo
timeFrame: through study completion, an average of 1 year
Locations:
city: Clermont-Ferrand
country: France
facility: Clermont-Ferrand University Hospital
state: Auvergne
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Christelle Destinval, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06849999: Kinesiophobia in Chronic Neck Pain
Official title: Evaluation of the Role of Kinesiophobia on Pain, Disability, and Quality of Life in Individuals with Chronic Neck Pain
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Neck Pain
Kinesiophobia
Keywords: Chronic pain
Kinesiophobia
Disability
Quality of Life
Lead sponsor: Fatih Sultan Mehmet Training and Research Hospital
Sponsor class: OTHER
First posted: 2025-02-27
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: * Adults aged 18 to 59
* Patients of both genders experiencing neck pain for at least 3 months

Brief summary: In this study, the effect of kinesiophobia on pain, disability, and quality of life in individuals with chronic neck pain will be evaluated. Neck pain is a common musculoskeletal disorder that can become chronic in some individuals. Kinesiophobia may lead to a reduction in physical activity due to fear of movement and re-injury, thereby increasing pain and disability. In this cross-sectional study, 57 participants will be assessed using the Visual Analog Scale (VAS), Tampa Scale for Kinesiophobia (TSK), Neck Disability Index (NDI), and the SF-36 Quality of Life Scale. Participants will be selected from individuals aged 18-59 who have experienced neck pain for at least 3 months, and those with a history of neurological disorders, spinal surgery, or pain treatment in the last 3 months will be excluded. This research aims to determine the effects of kinesiophobia on chronic neck pain, thereby contributing to the development of more effective treatment strategies. Written informed consent will be obtained from all participants.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 to 59
* Patients of both genders experiencing neck pain for at least 3 months

Exclusion Criteria:

* Patients with neurological deficits
* Patients with any neurological disorder
* Patients with a history of spinal fractures, spinal tumors, or spinal infections
* Patients with a history of spinal surgery
* Patients with any congenital spinal anomaly
* Patients with vestibular disorders
* Patients taking antidepressant and antihypertensive medications
* Patients unwilling to participate in the study
* Patients who have received any pain treatment in the last 3 months
* Patients who have engaged in any strenuous physical activity within the 24 hours prior to the assessment

Primary outcomes:
measure: tampa kinesiophobia scale
timeFrame: 1 day
measure: sf 36
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Liv hospital Vadistanbul
Study officials:
affiliation: Liv hospital vadistanbul
name: pmr specialist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00937599: Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Nutritive Microcirculatory Patterns
Official title: The Effect of Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Skin Microcirculatory Patterns in Obese Female Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: obese
brazil nuts
oxidative stress
microcirculatory
metabolic profile
Lead sponsor: Rio de Janeiro State University
Sponsor class: OTHER
First posted: 2009-07-13
Enrollment: 18
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose this research is to check if Brazil Nuts consumed improvement the metabolic profile, state redox and endothelial function in obese adolescents.

Detailed description: The purpose this research is to check if Brazil Nuts consumed improvement the metabolic profile (lipid profile, glucose, insulin), state redox (about glutathione peroxidase, isoprostane and LDL-ox) and endothelial function (by videocapillaroscopy) in obese adolescents (12-18 years).

Eligibility criteria: Inclusion Criteria:

pubertal girls obese (BMI \> 30 kg/m) -

Exclusion Criteria:

Consumption of nuts Loss weight before the research chronic disease (hypertension)

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rio de janeiro,
country: Brazil
facility: Laboratory for Clinical and Experimental Research in Vascular Biology (BioVasc), Biomedical Center, State University of Rio de Janeiro
state: RJ
Study officials:
References:
citation: Maranhao PA, Kraemer-Aguiar LG, de Oliveira CL, Kuschnir MC, Vieira YR, Souza MG, Koury JC, Bouskela E. Brazil nuts intake improves lipid profile, oxidative stress and microvascular function in obese adolescents: a randomized controlled trial. Nutr Metab (Lond). 2011 May 28;8(1):32. doi: 10.1186/1743-7075-8-32.
Clinical trial NCT05954299: Vincere Biobank Research Protocol
Official title: Vincere Biobank Research Protocol
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Keywords: Cancer
Biobank
Biorepository
Lead sponsor: Vincere Cancer Center
Sponsor class: OTHER
First posted: 2023-07-20
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults age 18 years and older of any gender and demographic group, including both healthy participants and those with disease.

Brief summary: The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older; any gender
* Able to donate a blood, urine, tissue, and/or other biospecimen sample
* Able to provide informed consent to participate in the study

Exclusion Criteria:

* Minors, under the age of 18 years
* Individuals who lack the capacity to give informed consent

Primary outcomes:
measure: Biobank
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Vincere Cancer Center
state: Arizona
Study officials:
affiliation: Vincere Cancer Center
name: Vershalee Shukla, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06999499: Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.
Official title: Development of Artificial Intelligence Algorithms to Help Detect Potential Melanomas, Using Images From the VECTRA 3D Whole Body 360 Imaging System, a 3D Whole-body Skin Scanner.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Naevi
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2025-05-31
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The background to this research is that frequent medical screening of the general population for melanoma is not feasible. The real challenge of this project is to develop an automatic process for detecting any potential melanoma. To this end, the project aims to design an algorithm to build a novel diagnostic aid that makes use of the similarity and disparity of pigmented lesions in the same patient. To achieve this, we need to obtain and structure a large database of images grouping all pigmented lesions per patient according to their similarities as perceived by dermatologists.


Eligibility criteria: Inclusion Criteria:

* Male or female aged 18 and over
* Patient with more than 15 nevi (moles) of various phototypes (I to III)
* Patient who has received information about the study and has not expressed any opposition
* Patient who is a beneficiary or entitled person under a social security scheme

Exclusion Criteria:

* Patients with phototype V
* Patients with chronic inflammatory skin diseases
* Claustrophobic patients
* Patients who are bedridden or handicapped
* Patients who are excluded from another research protocol at the time of collection of the non-objection.
* Patients covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women),
* Any other reason which, in the investigator's opinion, could interfere with the evaluation of the research objectives.

Primary outcomes:
measure: development and validation of algorithms to identify lesions clinically suspected of being melanoma by a dermatologist (potentially malignant and/or ugly duckling).
timeFrame: from enrollement to until 6 month
Secondary outcomes:
measure: concordance rate for malignant annotations
timeFrame: From enrollement to 6 month after
measure: concordance rate for ugly duckling
timeFrame: From enrollement to 6 month after
measure: calculation of the proportion of melanomas confirmed by anatomopathology
timeFrame: From enrollement to 6 month after
Other outcomes:
Locations:
city: Marseille
country: France
facility: Hôpital de la Conception
Study officials:
References:
Clinical trial NCT01759199: The Six-minute Stepper Test as an Outcome Measure of Exercise Tolerance During Pulmonary Rehabilitation in With Chronic Obstructive Pulmonary Disease (COPD) Patients(STEPPER)?
Official title: The Six-minute Stepper Test : Marker of Exercise Tolerance's Evolution During Pulmonary Rehabilitation in Patients With COPD ?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
ST6: The six minute Stepper Test
Conventional respiratory rehabilitation
Pulmonary rehabilitation
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
Collaborators: name: Ministry of Health, France
First posted: 2013-01-03
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to show if the six-minute stepper test (ST6) is a sensible marker of exercise tolerance evolution during a pulmonary rehabilitation program in people with all stages of severity of Chronic Obstructive Pulmonary Disease (COPD).

Detailed description: Currently, the reference test in assessing functional capacity in COPD patients during pulmonary rehabilitation is the six-Minute Walking Test (6MWT). However, the realization of the 6MWT requires a 30m-long corridor, according to the American Thoracic Society Guidelines. Lack of sufficient space can prevent the realization of 6MWT, especially for private practitioner pulmonologists, and also in hospitals. The six-minute stepper test (ST6) which can be performed in a normal room, should be an interesting alternative.

Eligibility criteria: Inclusion Criteria:

* Patient with COPD wtih all stages of severity
* Hospitalized in the pulmonary rehabilitation unit in the hospital of Morlaix, with a 3 weeks pulmonary rehabilitation course

Exclusion Criteria:

* Pneumonectomy, Lobectomy less than 6 months
* orthopedic problem
* Balance disorder
* Weight \> 110kg

Primary outcomes:
measure: The number of steps to The Six-minute Stepper Test (ST6)
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Brest,
country: France
facility: Brest University Hospital
state: Brittany
city: Morlaix
country: France
facility: Hospital of Morlaix
state: Brittany
city: Morlaix, Brittany
country: France
facility: Hospital of Morlaix
Study officials:
affiliation: Brest University Hospital Brest,, Brittany, France 29200
name: FRANCIS COUTURAUD, MD,PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital of Morlaix Morlaix, Brittany, France 29600
name: CATHERINE LE BER-MOY, DR.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital of Morlaix Morlaix, Brittany, France 29600
name: CHANTAL LOCHON, DR.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00482599: Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)
Official title: A Multicenter, Parallel Group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Anesthesia, General
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-06-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy and pharmacokinetics of Org 25969 in subjects with normal or impaired renal function and to evaluate the safety of Org 25969 in subjects with impaired renal function.


Eligibility criteria: Inclusion Criteria:

* ASA class 1 - 3 for renally impaired patients, ASA class 1-2 for control group
* Age at least 18 years
* Scheduled for general anesthesia without further need for muscle relaxation other than one single dose of 0.6 mg.kg-1 rocuronium
* Scheduled for surgical procedures in the supine position
* Written informed consent
* Creatinine clearance (CLCR) \< 30 mL/min for renally impaired group, CLCR = 80 mL/min for control group

Exclusion Criteria:

* Known or suspected neuromuscular disorders impairing NMB
* Known or suspected (family) history of malignant hyperthermia
* Known or suspected allergy to narcotics, muscle relaxants or other medication used during general anesthesia
* Use of medication known to interfere with NMBA based on the dose and the time of administration, such as antibiotics, anticonvulsants and Mg2+
* Pregnancy
* Childbearing potential without using any of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner ( \> 6 months), intrauterine device, abstinence
* Breast-feeding
* Prior participation in any trial with Org 25969
* Participation in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into trial 19.4.304, or for the UK only: Participation in another clinical trial, within 30 days of entering into trial 19.4.304.

Primary outcomes:
measure: Time from start administration of Org 25969 to recovery T4/T1 ratio to 0.9
timeFrame: After surgery
Secondary outcomes:
measure: Time from start administration of Org 25969 to recovery T4/T1 ratio to 0.7 and 0.8
timeFrame: After surgery
Other outcomes:
Locations:
Study officials:
References:
citation: Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010 Jan;104(1):31-9. doi: 10.1093/bja/aep340.
Clinical trial NCT00334399: Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: alpa-glucosidase inhibitor,Biguanide
Lead sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2006-06-07
Sex: ALL
Minimum age (years): 20
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetic patients treated with Biguanide
* Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

* Type 1 diabetes
* Patients treated with other antidiabetic drugs or Insulin

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aichi
country: Japan
city: Chiba
country: Japan
city: Fukuoka
country: Japan
city: Gifu
country: Japan
city: Gunma
country: Japan
city: Hokkaido
country: Japan
city: Ibaragi
country: Japan
city: Kanagawa
country: Japan
city: Kumamoto
country: Japan
city: Miyazaki
country: Japan
city: Osaka
country: Japan
city: Saitama
country: Japan
city: Tochigi
country: Japan
Study officials:
affiliation: Sanwa Kagaku Kenkyusho Co., Ltd.
name: Clinical Study Group, Clinical Development Dept.
role: STUDY_DIRECTOR
References: